ClinicalTrials.gg
CompletedNCT05727839Updated Nov 9, 2026

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

A Phase 1 interventional study of JCXH-211 Injection in Cutaneous Tumor and Malignant Solid Tumor, sponsored by Immorna Biotherapeutics, Inc.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Primary conditionNeoplasms(registry's first term: Skin Neoplasms)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Skin Neoplasms, so we do not take that as its main condition. It is compared within Neoplasms.

Sponsored by Immorna Biotherapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

: A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors

Read the detailed description

The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase

1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.

02

Conditions studied

  • Cutaneous Tumor
  • Malignant Solid Tumor

Browse trials for

Keywords

  • Tumor
  • Intratumoral injection
03

In context

Neoplasms Many cancers

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 19 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Immorna Biotherapeutics, Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Compared within Neoplasms: the study is open to many cancers; the registry's first condition term is Skin Neoplasms. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients 18-75
  • Patients with malignant solid tumors that have been diagnosed by pathology and/or cytology
  • Patients who have progressed on or who cannot tolerate available therapies or for whom curative therapy does not exist
  • Patients with at least one non-injected measurable tumor lesion per v1.1
  • Patients with lesions suitable for intratumoral injection (the lesion length is at least 10mm and not exceeding 80mm)
  • Patients enrolled in the Skin/subcutaneous lesions and deep (visceral) lesions stages of Phase Ia must agree to provide pre- and post-treatment tumor tissues
  • Patients must have adequate organ and marrow functions
  • Patients with treated are eligible if meeting protocol's requirement
  • Patients must be ≥ 4 weeks beyond treatment with any chemotherapy (6 weeks for nitrosoureas or mitomycin C), hormonal, biological, targeted agents, other therapy or radiotherapy

Exclusion criteria

Exclusion Criteria:

  • Patients who have received prior IL-12 either alone or as part of a treatment regimen
  • Patients who have received prior therapy with an immuno-oncology agent and were discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE)
  • Patients requiring therapeutic doses of anticoagulation
  • Patients with tumors that impinge on major airways, blood vessels, or nerve bundles
  • Patients with a history of disease that has the possibility of recurrence or active autoimmune disease that requires medications
  • Patients who had a major surgical procedure within 4 weeks prior to the first dose of study treatment
  • Current or prior use of immunosuppressive medication within 2 weeks prior to the first dose of study treatment
  • Patient with history of solid organ or allogenic bone marrow transplantation
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Dose escalation

    Dose escalation study of intratumoral injection of JCXH-211 injection into cutaneous/subcutaneous lesions

    Drug: JCXH-211 Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity

    Dose limiting toxicity, evaluated in the Phase Ia, which will be used to determine the MTD and to determine dose escalation.

    Time frame: Within 28 days or 14days after the first dose

  2. Incidence of adverse events (Safety and Tolerability)

    Safety and tolerability as determined by the incidence of adverse events (AEs), including severe AEs and serious AEs (SAEs).

    Time frame: From consent to 28 days after the last dose of study drug

Secondary outcomes

  1. Duration of response (DoR)

    Duration of response is defined as the time from the first assessment of tumor as CR or PR to the first assessment as progressive disease or death from any cause.

    Time frame: 6 months after the last patient is enrolled.

  2. Disease control rate (DCR)

    Disease control rate is defined as the proportion of patients with CR or PR or stable disease (SD) with the DoR ≥ 12weeks observed from Day 1 to disease progression.

    Time frame: 6 months after the last patient is enrolled.

  3. Progression-free survival (PFS)

    Progression-free survival is defined as the time from Day 1 to disease progression or death from any cause, whichever occurs earlier.

    Time frame: 6 months after the last patient is enrolled.

  4. Overall survival (OS)

    Overall survival is defined as the time from Day 1 until death due to any cause.

    Time frame: 6 months after the last patient is enrolled.

  5. Objective response rate (ORR)

    Objective response rate is defined as the proportion of patients that achieve a complete response (CR) or partial response (PR) during the study participation.

    Time frame: 6 months after the last patient is enrolled.

  6. Clinical benefit rate (CBR)

    Clinical benefit rate is defined as the proportion of patients with the best response of CR, PR, or SD (duration ≥ 24 weeks) throughout the study from Day 1 of treatment with the study drug to disease progression.

    Time frame: 6 months after the last patient is enrolled.

07

Study locations

2 sites
  • The George Washington Medical Faculty Associates
    Washington D.C., District of Columbia 20037, United States
  • Sun Yat-sen University Cancer Center
    Guangdong, Guangzhou 510060, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Sep 2024, 19 months.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 19 months is below that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2023
First posted
Feb 14, 2023
StartActual
Feb 24, 2023
Primary completionActual
Sep 30, 2024
CompletionActual
Sep 30, 2024
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: oversight details and design details
1 update, last Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Minor edits only
    + 2 other changes: oversight details and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05727839
Lead sponsor
Immorna Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Feb 14, 2023
Start date
Feb 24, 2023
Primary completion
Sep 30, 2024
Completion
Sep 30, 2024
Last update
Nov 9, 2026

Study contacts

Xu ruihua, President
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lipid Nanoparticle Encapsulated Self-replicating RNA Encoding Human IL-12 JCXH-211

Start the discussion